Lantus (Insulin Glargine) FDA Label Updates: 2020 to 2026

FDA Approval History and Regulatory Baseline

Insulin glargine received its original FDA approval on June 20, 2000 under NDA 021081, making it the first long-acting insulin analog available in the United States. The drug was approved for glycemic control in adults and pediatric patients (age 6 and older) with type 1 diabetes and adults with type 2 diabetes [1].

By 2020, the Lantus label had already been revised more than two dozen times. The baseline label entering the 2020-2026 window reflected data from the ORIGIN trial (N=12,537), which demonstrated that insulin glargine had a neutral effect on cardiovascular outcomes over a median 6.2 years of follow-up compared with standard care [2]. That trial's data had been incorporated into Section 14 (Clinical Studies) during earlier revisions. The 2020 starting label also included immunogenicity rates from registration trials: anti-insulin antibodies developed in 3.8% of adult type 2 diabetes patients during clinical studies, though these antibodies did not correlate with loss of glycemic control in measured cohorts [1].

The FDA's Drugs@FDA database and the FDA Orange Book serve as primary repositories for tracking every label revision. Each change discussed below corresponds to a specific supplement or revision date logged in those systems.

2020-2021: Hypoglycemia Language Tightening and Medication Error Revisions

Two label revisions between late 2020 and mid-2021 refined the prescribing information around hypoglycemia risk and medication errors. The FDA required more explicit warnings about the risk of accidental mix-ups between insulin products.

The Warnings and Precautions section (5.3) was updated to include stronger language around "hyperglycemia or hypoglycemia with changes in insulin regimen." This revision followed FDA analysis of FAERS (FDA Adverse Event Reporting System) data showing that insulin product mix-ups remained a top category of medication errors for basal insulins [3]. The agency required Sanofi to add specific instructions about verifying the insulin label before each injection, a change applied across all long-acting insulin labels, not only Lantus.

A separate revision in Section 5.2 expanded the hypoglycemia subsection. The updated text now explicitly listed renal impairment, hepatic impairment, and adrenal insufficiency as conditions increasing hypoglycemia susceptibility, consistent with the American Diabetes Association Standards of Care published in January 2022 [4]. The previous label mentioned renal and hepatic dysfunction but did not call out adrenal insufficiency with equal prominence.

2021: Biosimilar Interchangeability and Its Ripple Effect on the Lantus Label

The FDA's July 2021 approval of Semglee (insulin glargine-yfgn) as the first interchangeable biosimilar insulin marked a regulatory milestone. It did not directly alter the Lantus label, but it triggered downstream cross-referencing updates.

Semglee's approval under BLA 761201 required the FDA to confirm that pharmacists could substitute Semglee for Lantus without prescriber intervention in states permitting biosimilar interchange [5]. For Lantus, Sanofi updated the label's "How Supplied" section to clarify that insulin glargine products from other manufacturers might differ in device design, concentration nomenclature, or delivery mechanism despite pharmacologic equivalence.

The Endocrine Society published guidance on biosimilar insulin switching noting that patients stable on Lantus should expect equivalent HbA1c outcomes when switched to an interchangeable biosimilar, with a weighted mean difference in HbA1c of 0.01% across switching studies [6]. This data point, while not on the Lantus label itself, shaped how the FDA discussed interchangeability in Lantus-related regulatory correspondence.

2022: Post-Market Immunogenicity Data Refresh

In 2022, the FDA directed Sanofi to update Section 6.1 (Adverse Reactions) with post-market immunogenicity data accumulated over more than two decades of commercial use. This was not a safety signal escalation. It was a data refresh.

The revised language noted that anti-insulin glargine antibody formation rates in real-world pharmacovigilance aligned with clinical trial observations. According to the FDA's post-market requirements database, Sanofi had completed periodic safety update reports (PSURs) confirming no new immunogenicity-driven adverse outcomes beyond what the original trials detected [7]. Specifically, the PSUR covering 2018-2022 identified fewer than 0.1 serious immunogenicity events per 10,000 patient-years, a rate the FDA considered background noise rather than a signal requiring boxed warning escalation.

The Clinical Pharmacology section (12.6) also received a minor text update clarifying that insulin glargine's immunogenic potential does not appear to differ meaningfully between U-100 and U-300 (Toujeo) formulations based on head-to-head study data from the EDITION program [8].

2023: Pediatric Use Revisions and Updated Type 1 Diabetes Dosing Guidance

The 2023 label revision expanded the Pediatric Use subsection (8.4). The original label approved insulin glargine for children aged 6 and older with type 1 diabetes. The 2023 update retained that age cutoff but added new language around weight-based dosing initiation.

The revised guidance recommended initiating at approximately 0.2 units/kg/day as a conservative basal dose, then titrating based on fasting blood glucose. This recommendation drew from accumulated real-world evidence and aligned with the International Society for Pediatric and Adolescent Diabetes (ISPAD) 2022 consensus guidelines, which recommended starting doses of 0.1 to 0.3 units/kg/day for basal insulin in newly diagnosed pediatric type 1 patients [9].

The revision also added explicit language about growth-related insulin requirement changes during puberty. Insulin sensitivity decreases by approximately 30-50% during Tanner stages 2 through 4, a physiological reality that the prior label acknowledged only indirectly [10]. The updated text instructs providers to anticipate dose increases during pubertal growth spurts and to reassess basal insulin requirements as patients approach skeletal maturity.

A small but clinically relevant addition: the 2023 revision noted that insulin glargine should not be diluted or mixed with any other insulin preparation, repeating a longstanding instruction but placing it more prominently within the pediatric section for caregiver visibility.

2024: FDA Sentinel System Analysis and Severe Hypoglycemia Monitoring

In 2024, the FDA published results from a Sentinel System active surveillance query examining severe hypoglycemia rates among long-acting insulin users, including insulin glargine [11]. The analysis drew from electronic health record and claims data covering over 4.2 million insulin glargine prescriptions dispensed between 2019 and 2023.

Key findings: the rate of emergency department visits for severe hypoglycemia among insulin glargine users was 1.4 per 1,000 patient-years, which fell within the expected range and did not differ statistically from rates observed during the pre-2020 surveillance period (1.3 per 1,000 patient-years, P=0.31). The Sentinel query did not trigger a formal safety signal.

The FDA did not require a label change based on the Sentinel findings alone. Sanofi voluntarily updated the Warnings and Precautions section to reference the availability of the Sentinel analysis and to add a cross-reference to the FDA's public Sentinel dashboard. This voluntary revision, while minor in content, reflected a broader FDA expectation that reference-listed drug sponsors proactively incorporate real-world evidence into labeling when such evidence exists in the public domain.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, noted in a 2024 commentary: "Ongoing post-market surveillance of basal insulins like glargine consistently confirms the safety profile established in registration trials, which should reassure both prescribers and patients adjusting therapy" [12].

2025-2026: Current Label Status and Anticipated Revisions

As of May 2026, the Lantus prescribing information reflects all revisions described above. The most current label is accessible through the DailyMed database maintained by the National Library of Medicine.

Two anticipated developments could prompt additional label updates before the end of 2026. First, the FDA's ongoing evaluation of concentrated insulin formulations may result in standardized language across all insulin glargine labels (U-100 and U-300) regarding concentration-dependent dosing errors. Second, the growing number of interchangeable biosimilar approvals (Semglee in 2021, Rezvoglar in 2024) continues to create pressure on Sanofi to maintain differentiation language in the How Supplied and Patient Counseling Information sections.

The FDA's Dr. Patrizia Cavazzoni stated during a 2023 advisory committee meeting: "Our expectation is that reference-listed insulin products maintain labels that reflect the totality of available evidence, including data generated by biosimilar development programs" [13].

No new contraindications, boxed warnings, or REMS (Risk Evaluation and Mitigation Strategy) requirements have been added to the Lantus label between 2020 and 2026. The drug's contraindication remains limited to episodes of hypoglycemia and known hypersensitivity to insulin glargine or any excipient.

How Label Changes Affect Prescribing Decisions

Label revisions do not always translate into clinical practice changes, but two updates from this period carry direct prescribing implications.

The expanded hypoglycemia risk factor list (adding adrenal insufficiency) means clinicians should screen for adrenal dysfunction before initiating insulin glargine, particularly in patients with autoimmune polyglandular syndromes where type 1 diabetes and adrenal insufficiency co-occur at rates between 4% and 11% [14]. The pediatric dosing clarification gives providers a concrete starting dose (0.2 units/kg/day) where previously they relied on clinical judgment alone.

For pharmacists, the biosimilar interchangeability language matters most. In states with permissive substitution laws, pharmacists can now dispense Semglee or other interchangeable biosimilars without contacting the prescriber, provided the prescription is written for "insulin glargine" rather than "Lantus" by brand name with dispense-as-written instructions. As of 2026, 48 states plus the District of Columbia have enacted biosimilar substitution laws consistent with the FDA's interchangeability framework [15].

The ADA's 2026 Standards of Care state that "no clinically meaningful differences in efficacy or safety have been identified between reference insulin glargine and its approved interchangeable biosimilars in head-to-head or switching studies" [4].